General
Preferred name
vosoritide
Synonyms
BMN-111 ()
P&D ID
PD055955
CAS
1480724-61-5
Tags
drug
Approved by
PMDA
EMA
FDA
First approval
2021
Drug indication
Achondroplasia
Drug Status
approved
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Vosoritide is a cyclic analogue of C-type natriuretic peptide (CNP) that has a longer half-life (duration of action) than the endogenous peptide . It comprises the 37 C-terminal amino acids from human CNP with the addition of proline and glycine (PG) at its N-terminal.
Vosoritide represents a novel mechanism which has the potential to treat mutant fibroblast growth factor receptor 3-driven achondroplasia, by stimulating endochondral ossification and thereby ameliorating impaired bone growth . (GtoPdb)
Compound Sets
4
DrugCentral
5480
DrugCentral Approved Drugs
5480
DrugMAP
DMM9XL2
Guide to Pharmacology
9068
External IDs
4
Properties
(calculated by RDKit )
Molecular Weight
4100.1
Hydrogen Bond Acceptors
61
Hydrogen Bond Donors
61
Rotatable Bonds
110
Ring Count
6
Aromatic Ring Count
3
cLogP
-20.99
TPSA
1739.73
Fraction CSP3
0.65
Chiral centers
32.0
Largest ring
53.0
QED
0.01
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Source data